How to make 80% return in three month with AgenAgenus Inc., an immuno-oncology company, focuses on the discovery and development of treatments that engage the bodys immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform that screens and generates therapeutic antibody drug candidates using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes. It is also developing Prophage, a heat shock protein-based autologous vaccine, which has completed Phase II clinical trials for the treatment of glioblastoma; and QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles.The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
AGEN trade ideas
AGEN short term shorting on downward triangleDecent chance to short to 3.90-4.00 range, depending on morning price action. Price consolidation occurred throughout the intraday trend and has now broken past the downward triangle pattern where the price has fallen below the 20 period BB. Stop loss should be at 4.15-4.20 range if price reverses past the EVWMA lines which act as our trend reversal signal mechanism.
Overvalued EarningsDespite reporting 4Q losses, Agenus Inc. (or the company) showed an increase in share price. This shocked many analysts and some concluded that this was due to the earnings report exceeding revenue. But now the "Earnings Hype" is over for revenue does not do anything to the EPS if the company cannot clear its margins and produce profit. This will lead to a bearish attitude in the near future which could mean profits for those who choose to sell short this stock.